A recent study suggests that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who end traditional diet and exercise regimens.
Research printed in a major health publication demonstrates that while overweight people can lose substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing such treatments must be aware of the risk of fast rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment mass within about one and a half years.
Weighing Treatments
The analysis, which looked at 37 of studies involving thousands of participants, compared the outcomes of the injectable medications with other pills.
Researchers note that individuals who shed pounds through diet and exercise generally see a less rapid creep back—approximately 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Doctors suggest the way of the drugs is key to understanding the accelerated rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the body to produce less of its endogenous GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' leads to hunger is no longer kept in check, making excessive eating a significant risk."
An Ongoing Disease?
Health authorities suggest the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
Professionals argue that, due to the significant potential of weight regain, the therapy should be considered ongoing.
This perspective is echoed by pharmaceutical companies, who say that the results "emphasize the chronic character of obesity," similar to managing diseases like hypertension.
User Experiences
Individuals who have come off the jabs explain a intense resurgence of cravings.
"It felt as if something activating and I was suddenly starving," recalled a patient.
This difficulty is worsened if users have not developed permanent dietary or behavioural modifications during treatment.
Widespread Interest
Figures show that a significant number of adults in the UK have used these injections in the past year, with demand remaining high.
- Adoption is more common among females than men.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Finally, experts caution that while these medications are potent agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on integrated behavioural support.